Ethics approval and consent to participate
This study involves human participants and was approved by Institutional Review Board of Liaoning Tumor Hospital (number: 20200622). Participants gave informed consent to participate in the study before…
Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial
